Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Enterprise Value: ¥1,921 Mil (As of Jul. 06, 2026) ***


SHSE:600613 Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613
53 GF Score
Price ¥4.82
GF Value ¥5.44
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Shenqi Pharmaceutical Investment Management Co Enterprise Value?

Shanghai Shenqi Pharmaceutical Investment Management Co SHSE:600613 +0.21% 53 Enterprise Value is ¥1,921 Mil as of Jul. 06, 2026. GuruFocus rates SHSE:600613 with a GF Score™ of 53/100 and a GF Value™ of ¥5.44 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value is ¥1,921 Mil. Shanghai Shenqi Pharmaceutical Investment Management Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ¥80 Mil. Therefore, Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-EBIT ratio for today is 23.99.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value is ¥1,921 Mil. Shanghai Shenqi Pharmaceutical Investment Management Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ¥80 Mil. Therefore, Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-EBITDA ratio for today is 23.99.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value is ¥1,921 Mil. Shanghai Shenqi Pharmaceutical Investment Management Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1,895 Mil. Therefore, Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-Revenue ratio for today is 1.01.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value is ¥1,921 Mil. Shanghai Shenqi Pharmaceutical Investment Management Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was ¥194 Mil. Therefore, Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-OCF ratio for today is 9.92.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value is ¥1,921 Mil. Shanghai Shenqi Pharmaceutical Investment Management Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥169 Mil. Therefore, Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-FCF ratio for today is 11.34.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Shanghai Shenqi Pharmaceutical Investment Management Co  (SHSE:600613) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1921.422/80.087
=23.99

Shanghai Shenqi Pharmaceutical Investment Management Co's current Enterprise Value is ¥1,921 Mil.
Shanghai Shenqi Pharmaceutical Investment Management Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥80 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1921.422/80.087
=23.99

Shanghai Shenqi Pharmaceutical Investment Management Co's current Enterprise Value is ¥1,921 Mil.
Shanghai Shenqi Pharmaceutical Investment Management Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥80 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1921.422/1895.383
=1.01

Shanghai Shenqi Pharmaceutical Investment Management Co's current Enterprise Value is ¥1,921 Mil.
Shanghai Shenqi Pharmaceutical Investment Management Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,895 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=1921.422/193.786
=9.92

Shanghai Shenqi Pharmaceutical Investment Management Co's current Enterprise Value is ¥1,921 Mil.
Shanghai Shenqi Pharmaceutical Investment Management Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥194 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1921.422/169.45
=11.34

Shanghai Shenqi Pharmaceutical Investment Management Co's current Enterprise Value is ¥1,921 Mil.
Shanghai Shenqi Pharmaceutical Investment Management Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥169 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Shenqi Pharmaceutical Investment Management Co Enterprise Value Related Terms


Shanghai Shenqi Pharmaceutical Investment Management Co Enterprise Value Historical Data

* Premium members only.

The historical data trend for Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Shenqi Pharmaceutical Investment Management Co Enterprise Value Chart

Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,295.46 4,069.26 3,636.36 3,144.37 2,824.02

Shanghai Shenqi Pharmaceutical Investment Management Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,830.93 3,001.65 2,706.55 2,824.02 2,682.59

SHSE:600613 vs LLY, JNJ, ABBV: Enterprise Value Comparison

For the Drug Manufacturers - General subindustry, Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Shenqi Pharmaceutical Investment Management Co Enterprise Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value falls into.


SHSE:600613
53GF Score
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Shenqi Pharmaceutical Investment Management Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as

Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of ¥1,921 Mil mean?
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a Enterprise Value of ¥1,921 Mil as of Jul. 06, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors.
Is Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value too high?
Shanghai Shenqi Pharmaceutical Investment Management Co's current Enterprise Value is ¥1,921 Mil. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value compare to LLY and JNJ?
Shanghai Shenqi Pharmaceutical Investment Management Co's Enterprise Value of ¥1,921 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. Shanghai Shenqi Pharmaceutical Investment Management Co's current Enterprise Value is ¥1,921 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.44, compared to a current price of ¥4.82 — trading 11.4% below its estimated fair value. The current Enterprise Value is ¥1,921 Mil. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current Enterprise Value is ¥1,921 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued. The current stock price of ¥4.82 is trading 11.4% below its estimated GF Value™ of ¥5.44. GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Modestly Undervalued.

Key valuation signals for SHSE:600613:

  • Enterprise Value: ¥1,921 Mil
  • GF Value™: ¥5.44 vs. price of ¥4.82 (11.4% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Shenqi Pharmaceutical Investment Management Co Business Description

Other Exchanges 900904:China
Address 128 Weihai Road, Room 613, Changfa Building, Shanghai, CHN, 200003
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd is mainly engaged in pharmaceutical production and distribution in China.
53GF Score

Get the complete analysis for SHSE:600613

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.82
Price
¥5.44
GF Value